

Theresa Hahn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4232468/publications.pdf>

Version: 2024-02-01

163
papers

5,124
citations

94433

37
h-index

98798

67
g-index

166
all docs

166
docs citations

166
times ranked

5831
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk factors for acute GVHD and survival after hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 296-307.	1.4	559
2	Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2010, 28, 1878-1887.	1.6	459
3	Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors. <i>Journal of Clinical Oncology</i> , 2013, 31, 2437-2449.	1.6	223
4	Prevalence of Hematopoietic Cell Transplant Survivors in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1498-1501.	2.0	210
5	Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen-Identical Sibling Transplants for Adults With Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 5728-5734.	1.6	159
6	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. <i>Blood</i> , 2009, 113, 3110-3118.	1.4	147
7	Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1543-1554.	2.0	135
8	Efficacy of High-Efficiency Particulate Air Filtration in Preventing Aspergillosis in Immunocompromised Patients With Hematologic Malignancies. <i>Infection Control and Hospital Epidemiology</i> , 2002, 23, 525-531.	1.8	122
9	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1-30.	2.0	109
10	Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1116-1123.	2.0	104
11	Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Pediatric Acute Lymphoblastic Leukemia: Update of the 2005 Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 505-522.	2.0	96
12	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Diffuse Large B Cell Lymphoma: Update of the 2001 Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 20-47.e30.	2.0	91
13	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myeloid Leukemia in Children: An Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1-25.	2.0	90
14	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 137-180.	2.0	90
15	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
16	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: An evidence-based review. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 4-37.	2.0	85
17	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Myelodysplastic Syndromes: An Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 137-172.	2.0	76
18	Ganciclovir Inhibits Lymphocyte Proliferation by Impairing DNA Synthesis. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 765-770.	2.0	74

#	ARTICLE	IF	CITATIONS
19	Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: Clinical, radiologic, and pathologic characteristics. <i>Mycopathologia</i> , 2005, 159, 181-188.	3.1	73
20	Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. <i>Cancer</i> , 2017, 123, 1828-1838.	4.1	73
21	gwasurvivr: an R package for genome-wide survival analysis. <i>Bioinformatics</i> , 2019, 35, 1968-1970.	4.1	72
22	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Children: An Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 823-861.	2.0	67
23	Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myelogenous Leukemia (AML) in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1442-1450.	2.0	64
24	Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1504-1510.	2.0	63
25	Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1471-1478.	2.0	62
26	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 443-468.	2.0	60
27	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Update of the 2006 Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 18-36.e6.	2.0	58
28	Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 861-873.	2.0	53
29	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: An evidence-based review. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 308-331.	2.0	52
30	Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1740-1744.	2.0	52
31	Arterial thrombosis in four patients treated with thalidomide. <i>Leukemia and Lymphoma</i> , 2005, 46, 239-242.	1.3	47
32	Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors. <i>Haematologica</i> , 2019, 104, 1084-1092.	3.5	46
33	Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. <i>Blood</i> , 2017, 130, 1585-1596.	1.4	45
34	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 932-940.	2.0	43
35	Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. <i>Haematologica</i> , 2017, 102, 1823-1832.	3.5	43
36	Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2086-2090.	2.0	42

#	ARTICLE	IF	CITATIONS
37	Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 744-751.	2.0	41
38	Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. <i>Blood Advances</i> , 2017, 1, 1056-1066.	5.2	40
39	Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1679-1686.	2.0	37
40	Thrombotic Microangiopathy after Allogeneic Blood and Marrow Transplantation Is Associated with Dose-Intensive Myeloablative Conditioning Regimens, Unrelated Donor, and Methylprednisolone T-Cell Depletion. <i>Transplantation</i> , 2004, 78, 1515-1522.	1.0	36
41	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 556-568.	1.4	34
42	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Pediatric Acute Lymphoblastic Leukemia: Update of the 2005 Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 979-981.	2.0	32
43	Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 2450-2456.	1.4	32
44	Long-Term Survival With Allogeneic Stem Cell Transplant and Donor Lymphocyte Infusion Following Salvage Therapy with Anti-CD52 Monoclonal Antibody (Campath) in a Patient with $\text{t}(11;17)$ Hepatosplenic T-Cell Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2004, 45, 1673-1675.	1.3	31
45	Long-Term Use of Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 587-592.	2.0	30
46	A Deletion Polymorphism in Glutathione-S-Transferase Mu (GSTM1) and/or Theta (GSTT1) Is Associated with an Increased Risk of Toxicity after Autologous Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 801-808.	2.0	30
47	Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. <i>Nature Communications</i> , 2022, 13, 807.	12.8	29
48	A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. <i>Bone Marrow Transplantation</i> , 2005, 35, 557-566.	2.4	27
49	Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. <i>Blood</i> , 2006, 107, 1970-1973.	1.4	26
50	Outcomes of Hematologic Malignancies after Unrelated Donor Hematopoietic Cell Transplantation According to Place of Residence. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 368-375.	2.0	26
51	Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1130-1137.	2.0	26
52	Seeing What's Out of Sight: Wireless Capsule Endoscopy's Unique Ability to Visualize and Accurately Assess the Severity of Gastrointestinal Graft-versus-Host-Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 643-648.	2.0	25
53	Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Is Underused as a Curative Therapy in Eligible Patients from the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1459-1464.	2.0	25
54	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma—type Richter syndrome. <i>Blood Advances</i> , 2021, 5, 3528-3539.	5.2	24

#	ARTICLE	IF	CITATIONS
55	Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk. <i>Journal of the Neurological Sciences</i> , 2016, 370, 13-17.	0.6	23
56	Engaging Patients in Setting a Patient-Centered Outcomes Research Agenda in Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1111-1118.	2.0	22
57	CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 497-508.	1.5	22
58	A Comparison of Measured Creatinine Clearance versus Calculated Glomerular Filtration Rate for Assessment of Renal Function before Autologous and Allogeneic BMT. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 574-579.	2.0	21
59	Granzyme B-Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2015, 195, 4514-4523.	0.8	21
60	Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation. <i>Blood</i> , 2018, 131, 2490-2499.	1.4	21
61	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 10-23.	2.0	20
62	The Evolution of the Evidence-Based Review: Evaluating the Science Enhances the Art of Medicine—Statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 819-822.	2.0	19
63	BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 641-648.	2.0	19
64	Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). <i>Blood Cancer Journal</i> , 2022, 12, 27.	6.2	19
65	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Update of the 2006 Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 16-17.	2.0	18
66	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6233.	12.8	17
67	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e7-e15.	2.0	16
68	HLA DR15 Antigen Status Does Not Impact Graft-versus-Host Disease or Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1302-1308.	2.0	15
69	Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex. <i>Blood Advances</i> , 2017, 1, 1717-1728.	5.2	15
70	Relationship between paid leave, financial burden, and patient-reported outcomes among employed patients who have undergone bone marrow transplantation. <i>Quality of Life Research</i> , 2019, 28, 1835-1847.	3.1	15
71	Ascertainment of Unmet Needs and Participation in Health Maintenance and Screening of Adult Hematopoietic Cell Transplantation Survivors Followed in a Formal Survivorship Program. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1968-1973.	2.0	14
72	A CIBMTR Prognostic Model for Progression-Free Survival (PFS) After Autologous Hematopoietic Cell Transplantation (AHCT) for Relapsed or Refractory Hodgkin Lymphoma (HL). <i>Blood</i> , 2011, 118, 499-499.	1.4	14

#	ARTICLE	IF	CITATIONS
73	Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 501-513.	2.5	13
74	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.	2.0	13
75	Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell-Associated Encephalopathy (ICE) Score. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e271-e274.	2.0	13
76	Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e89-e97.	2.0	12
77	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <i>Cancer</i> , 2021, 127, 609-618.	4.1	12
78	Identification and Utilization of Donor and Recipient Genetic Variants to Predict Survival After HCT: Are We Ready for Primetime?. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 45-58.	2.3	11
79	Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. <i>Bone Marrow Transplantation</i> , 2019, 54, 497-507.	2.4	11
80	First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study. <i>British Journal of Haematology</i> , 2020, 190, 222-235.	2.5	10
81	Evidence-Based Reviews and the Role of Blood and Marrow Transplantation in the Treatment of Selected Diseases: An ASBMT Policy Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 523-525.	2.0	9
82	Methodology for Updating Published Evidence-Based Reviews Evaluating the Role of Blood and Marrow Transplantation in the Treatment of Selected Diseases: A Policy Statement by the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 761-762.	2.0	9
83	Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 689-698.	2.0	9
84	Excess diagnosis of non-Hodgkin's lymphoma during spring in the USA. <i>Leukemia and Lymphoma</i> , 2007, 48, 357-366.	1.3	8
85	Validation of genetic associations with acute GVHD and nonrelapse mortality in DISCOVeRY-BMT. <i>Blood Advances</i> , 2019, 3, 2337-2341.	5.2	8
86	Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 187-195.	2.5	8
87	Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study. <i>Lancet Haematology</i> , 2020, 7, e715-e723.	4.6	8
88	Genome-Wide Association Analyses Identify Variants in IRF4 Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility. <i>Frontiers in Genetics</i> , 2021, 12, 554948.	2.3	8
89	Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation. <i>EClinicalMedicine</i> , 2021, 40, 101093.	7.1	8
90	Multiple functional variants in the IL1RL1 region are pretransplant markers for risk of GVHD and infection deaths. <i>Blood Advances</i> , 2019, 3, 2512-2524.	5.2	7

#	ARTICLE	IF	CITATIONS
91	The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1747-1756.	2.0	7
92	Combined Donor and Recipient Non-HLA Genotypes Show Evidence of Genome Wide Association with Transplant Related Mortality (TRM) after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (URD-BMT) (DISCOVeRY-BMT study). <i>Blood</i> , 2015, 126, 61-61.	1.4	7
93	Common Genetic Variants Are Associated with Accelerated Bone Mineral Density Loss after Hematopoietic Cell Transplantation. <i>PLoS ONE</i> , 2011, 6, e25940.	2.5	6
94	Population-Based Analysis of Hematologic Malignancy Referrals to a Comprehensive Cancer Center, Referrals for Blood and Marrow Transplantation, and Participation in Clinical Trial, Survey, and Biospecimen Research by Race. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1488-1494.	2.0	6
95	Financial Hardship after Hematopoietic Cell Transplantation: Lack of Impact on Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 345-347.	2.5	6
96	Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 496-503.	2.5	6
97	Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma. <i>JAMA Network Open</i> , 2021, 4, e2128373.	5.9	6
98	High Frequency and Early Onset of Bone Mineral Density Loss Following Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 2011-2011.	1.4	6
99	Histopathologic verification of acute leukemia (AL) in a cohort of 463 post-Chernobyl patients from Belarus, Russia and Ukraine. <i>Leukemia Research</i> , 2004, 28, 1273-1280.	0.8	5
100	Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1369-1374.	2.0	5
101	Evidence for Heterogeneous Genetic Associations with Acute Lymphoblastic Leukemia (ALL) By Cytogenetics and Sex in High-Risk Patients Treated with Matched Unrelated Donor Allogeneic Blood or Marrow Transplant (URD-BMT). <i>Blood</i> , 2015, 126, 2621-2621.	1.4	5
102	Prospective Assessment of Familial Financial Hardship after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S72.	2.0	4
103	Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 77-85.	2.4	4
104	Low-Level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen-Specific T Cells after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2147-2154.	2.0	4
105	Serological Response to Vaccination after Autologous Transplantation for Multiple Myeloma Is Associated with Improved Progression-Free and Overall Survival. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 245.e1-245.e8.	1.2	4
106	A Study of Predictors of Clinical Outcomes and Healthcare Utilization in Children with Sickle Cell Disease Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 528-528.	1.4	4
107	BuCy Provides Equivalent Outcomes to VCyTBI as Conditioning Prior to Auto-SCT in Patients with Relapsed/Refractory NHL and Is a Valuable Option in Older (>=60 years) Patients.. <i>Blood</i> , 2008, 112, 2176-2176.	1.4	4
108	Optimizing the Timing of Allogeneic Blood or Marrow Transplantation (BMT) in a Prospective Cohort of Relapsed or Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011, 118, 3096-3096.	1.4	4

#	ARTICLE	IF	CITATIONS
109	Self-determinism: alloBMT for AML. <i>Blood</i> , 2011, 117, 2080-2081.	1.4	3
110	Autologous hematopoietic stem cell transplantation and maintenance therapy for multiple myeloma. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 71-83.	1.6	3
111	The Impact of Pre-Transplant Depression on Outcomes of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 265-265.	1.4	3
112	Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States. <i>Scientific Reports</i> , 2021, 11, 23284.	3.3	3
113	HLA DR15 and Immunobiologic Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 371.	2.0	2
114	Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2008, 49, 1494-1500.	1.3	2
115	BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 651-653.	2.4	2
116	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1928-1935.	2.0	2
117	Optical Coherence Tomography for Quantifying Human Cutaneous Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 271.e1-271.e8.	1.2	2
118	Fatal Hyperacute Graft-versus-Host Disease following Denileukin Diftitox Treatment for Recurrent T Cell Lymphoma after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 887-890.	2.0	1
119	Value of a Consensus Panel to Adjudicate Cause-Specific Mortality after Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (URD-HCT) for Use As the Primary Endpoint in a Genome-Wide Association Study (GWAS). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S35-S36.	2.0	1
120	Impact of Race on Graft-Versus-Host Disease Rates after HLA-Matched Sibling Bone Marrow or Peripheral Blood Hematopoietic Cell Transplantation: Comparison of North American Caucasian Versus Japanese Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S34-S35.	2.0	1
121	Replicated Risk Index of Patient Functional Status Prior to Allogeneic Hematopoietic Cell Transplantation Predicts Healthcare Utilization and Survival. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 875.e1-875.e9.	1.2	1
122	The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT).. <i>Blood</i> , 2008, 112, 1138-1138.	1.4	1
123	Effect of Immune Reconstitution on Survival after Autologous Hematopoietic Cell Transplant for B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 3173-3173.	1.4	1
124	Evolution of Multiparametric Flow Cytometry Testing for Minimal Residual Disease Assessment in Multiple Myeloma and Its Impact on Clinical Outcomes: A Single Institution Experience. <i>Blood</i> , 2016, 128, 2274-2274.	1.4	1
125	Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant.. <i>Blood</i> , 2007, 110, 3049-3049.	1.4	1
126	Glutathione-S-Transferase M1 (GSTM1) and T1 (GSTT1) Deletion Polymorphisms Predict Regimen-Related Toxicity after Autologous and Allogeneic Blood and Marrow Transplantation (BMT).. <i>Blood</i> , 2007, 110, 1982-1982.	1.4	1

#	ARTICLE	IF	CITATIONS
127	Genome-Wide Association Study of Overall and Progression-Free Survival after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT study). <i>Blood</i> , 2015, 126, 397-397.	1.4	1
128	Financial Burden and Patient-Reported Outcomes after Hematopoietic Cell Transplantation: Impact of Pre-Treatment Awareness of Transplant-Associated Costs. <i>Blood</i> , 2017, 130, 684-684.	1.4	1
129	Managing cardiac amyloidosis: Auto or allotransplant?. <i>American Journal of Hematology</i> , 2011, 86, 885-886.	4.1	0
130	Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (AlloPBHCT) with TBI-Based Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S30-S31.	2.0	0
131	Patterns of Referral for, and Utilization of, Blood and Marrow Transplantation (BMT) By Race. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S110-S111.	2.0	0
132	Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease. <i>Leukemia Research Reports</i> , 2014, 3, 28-31.	0.4	0
133	Measuring serological response to vaccination before and after autologous hematopoietic cell transplantation in multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e44-e45.	0.4	0
134	Neither Donor nor Recipient Mitochondrial Haplotypes Are Associated with Unrelated Donor Transplant Outcomes: A Validation Study from the CIBMTR. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 836.e1-836.e7.	1.2	0
135	Human Leukocyte Antigen (HLA) DR15 Is Associated with Reduced Incidence of Acute GvHD in HLA-Matched Allogeneic HSCT but Does Not Impact Survival.. <i>Blood</i> , 2004, 104, 3319-3319.	1.4	0
136	Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT).. <i>Blood</i> , 2006, 108, 3033-3033.	1.4	0
137	Glutathione-S-Transferase M1 (GSTM1) and T1 (GSTT1) Single Nucleotide Polymorphisms (SNPs) Predict Regimen-Related Toxicity after Autologous and Allogeneic Blood and Marrow Transplantation (BMT).. <i>Blood</i> , 2006, 108, 47-47.	1.4	0
138	Analysis of Donor Age and Absolute Lymphocyte Count Recovery as Prognostic Indicators of Survival after Allogeneic Blood or Marrow Transplantation.. <i>Blood</i> , 2006, 108, 5252-5252.	1.4	0
139	Wireless Capsule Endoscopy (WCE) Is an Important Diagnostic and Management Tool of Gastrointestinal (GI) Acute and Chronic Graft Versus Host Disease (GVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) and Identifies Gastroparesis as a Prominent Complication of GI GVHD.. <i>Blood</i> , 2007, 110, 2985-2985.	1.4	0
140	Risk Factors for Acute Graft-Versus-Host Disease (GvHD) after Related Donor HLA-Matched Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Adult Leukemia: Identification of Modifiable and Non-Modifiable Factors. A CIBMTR Study.. <i>Blood</i> , 2007, 110, 1069-1069.	1.4	0
141	Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 5130-5130.	1.4	0
142	Gemtuzumab Ozogamicin (GO) and Continuous Infusion Cytarabine (ARA-C) for Relapsed/Refractory Acute Myeloid Leukemia (AML) Prior to Allogeneic Stem Cell Transplantation (SCT).. <i>Blood</i> , 2008, 112, 952-952.	1.4	0
143	Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults. <i>Blood</i> , 2008, 112, 51-51.	1.4	0
144	Clinical and Genetic Factors Underlying Acute Bone Mineral Density Loss by 100 Days after Blood and Marrow Transplantation: A Potential Early Regimen-Related Complication. <i>Blood</i> , 2008, 112, 52-52.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Diverse Roles of Hepatocyte Growth Factor (HGF) in Normal Karyotype Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 3107-3107.	1.4	0
146	Comparison of Prognostic Models for Autologous Hematopoietic Stem Cell Transplantation (AHCT) for Relapsed Hodgkin Lymphoma.. Blood, 2009, 114, 1215-1215.	1.4	0
147	Pharmacokinetics of Mycophenolic Mofetil and Metabolites in Allogeneic Transplant: Determination of Maximum Dose Schedule and Route of Administration.. Blood, 2009, 114, 2276-2276.	1.4	0
148	Significant Improvement In Day 100 and 1-Year Overall Survival In Patients Who Underwent Myeloablative Allogeneic Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005. Blood, 2010, 116, 3509-3509.	1.4	0
149	Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors “ An Analysis of the CIBMTR. Blood, 2010, 116, 897-897.	1.4	0
150	Significant Improvement In Overall Survival In Patients Who Underwent Autologous Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005. Blood, 2010, 116, 2389-2389.	1.4	0
151	Fludarabine, Melphalan and Low Dose Total Body Irradiation for Reduced Intensity Conditioning (RIC) Prior to Allogeneic Hematopoietic Cell Transplantation (AlloHCT). Blood, 2011, 118, 4570-4570.	1.4	0
152	Micro Dose Methotrexate (MTX) Is Equivalent to Full Dose MTX and Superior to No MTX for Acute Graft-Versus-Host Disease Prophylaxis. Blood, 2011, 118, 3038-3038.	1.4	0
153	HLA DR15 Antigen Status Does Not Impact Graft-Versus-Host Disease or Disease-Free Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies. Blood, 2011, 118, 3094-3094.	1.4	0
154	Short Course of Levofloxacin During Neutropenia Prevents Early and Late Bacteremia Episodes After Allogeneic Blood and Marrow Transplantation (alloBMT). Blood, 2012, 120, 4141-4141.	1.4	0
155	Analysis Of Immune Cell Populations Before and After Autologous Hematopoietic Stem Cell Transplant For Multiple Myeloma: Association With Early Recovery Of Absolute Lymphocyte Count and Progression-Free Survival. Blood, 2013, 122, 3348-3348.	1.4	0
156	Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial. Blood, 2014, 124, 209-209.	1.4	0
157	Replication of Candidate SNP Survival Analyses and Gene-Based Tests of Association with Survival Outcomes after an Unrelated Donor Blood or Marrow Transplant: Results from the Discovery-BMT Study. Blood, 2016, 128, 71-71.	1.4	0
158	Exome Array Analyses Identify New Genes Influencing Survival Outcomes after HLA-Matched Unrelated Donor Blood and Marrow Transplantation. Blood, 2016, 128, 518-518.	1.4	0
159	Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A CIBMTR Analysis. Blood, 2016, 128, 842-842.	1.4	0
160	Role of Donor Source on Clinical Outcomes and Inpatient Resource Utilization for Hematopoietic Cell Transplantation in Children with Acute Leukemia. Blood, 2016, 128, 3575-3575.	1.4	0
161	Identification of Immune Phenotypes Associated with Improved Progression Free and Overall Survival for Patients with Multiple Myeloma Treated with Autologous Hematopoietic Cell Transplantation. Blood, 2016, 128, 3454-3454.	1.4	0
162	Exome Array Analyses Identify Low-Frequency Germline Variants Associated with Increased Risk of AML in a HLA-Matched Unrelated Donor Blood and Marrow Transplant Population. Blood, 2016, 128, 42-42.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Impact of conditioning regimen on peripheral blood hematopoietic cell transplant. World Journal of Clinical Oncology, 2019, 10, 86-97.	2.3	0